-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $264

Benzinga·08/04/2026 16:41:04
Listen to the news
Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $254 to $264.